GlassScriptPhysician profile
Hope A Haffizulla
NPI 1689645327
$3,630.53
in general payments reported to CMS, 2019-2025
36 companies · $600 in 2025
The $600 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $821 · 2021: $285 · 2022: $799 · 2023: $331 · 2024: $48.37 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $695.32 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $646.23 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $268.82 | 2020-2025 | |
| Lilly USA, LLC | $268.40 | 2019-2023 | Mounjaro, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $180.84 | 2022-2025 | |
| Allergan, INC. | $156.90 | 2020 | |
| Merck Sharp & Dohme LLC | $147.97 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $127.08 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.98 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.50 | 2025 | |
| Glaxosmithkline, LLC. | $113.75 | 2020-2022 | |
| Amgen INC. | $106.18 | 2019-2024 | Prolia, Evenity |
| Pfizer INC. | $83.63 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.84 | 2019-2021 | |
| Akcea Therapeutics, INC. | $49.18 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $44.07 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $42.42 | 2022-2023 | Xarelto |
| Horizon Therapeutics Plc | $36.43 | 2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $35.26 | 2019-2021 | |
| Shire North American Group INC | $30.68 | 2019 | |
| Corium, LLC | $27.95 | 2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $27.91 | 2022 | |
| Daiichi Sankyo INC. | $24.66 | 2022 | |
| Lundbeck LLC | $21.80 | 2023 | Vyepti |
| Ultragenyx Pharmaceutical INC. | $19.40 | 2019 | |
| Eisai INC. | $18.59 | 2021 | |
| Boston Scientific Corporation | $18.12 | 2023 | |
| Ironshore Pharmaceuticals INC. | $16.81 | 2020 | |
| Atricure, INC. | $16.17 | 2022 | |
| Abbott Laboratories | $16.09 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $15.41 | 2019 | |
| Mylan Specialty L.P. | $14.22 | 2020 | |
| Currax Pharmaceuticals LLC | $13.34 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.13 | 2021 | |
| Forte Bio-Pharma LLC | $12.30 | 2019 | |
| Esperion Therapeutics, INC. | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hope Haffizulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.